GlassScriptPhysician profile
Cynthia Baxter
NPI 1033732276
$6,217.81
in general payments reported to CMS, 2019-2025
21 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $1,367 · 2023: $2,342 · 2024: $738 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.53 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,208.66 | 2021-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $370.09 | 2023 | Quviviq |
| Lundbeck LLC | $328.27 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $325.76 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $256.95 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $242.18 | 2022-2024 | Lybalvi, Aristada |
| Bausch Health US, LLC | $153.60 | 2022-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $140.08 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $138.37 | 2025 | Cobenfy |
| Almatica Pharma LLC | $130.73 | 2022-2023 | Gralise |
| Sunovion Pharmaceuticals INC. | $108.65 | 2022 | |
| Corium, LLC | $103.41 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $94.30 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $91.31 | 2022-2023 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $90.43 | 2024-2025 | Qelbree |
| Tris Pharma INC | $82.07 | 2023-2025 | Onyda Xr, Dyanavel Xr |
| Neurocrine Biosciences, INC. | $80.12 | 2021-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $35.62 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $22.06 | 2023 | Jornay Pm |
| Indivior INC. | $19.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.